These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 4038339)

  • 1. Antithrombotic and bleeding effects of a low molecular weight heparin fraction.
    Pangrazzi J; Abbadini M; Zametta M; Naggi A; Torri G; Casu B; Donati MB
    Biochem Pharmacol; 1985 Sep; 34(18):3305-8. PubMed ID: 4038339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits.
    Carter CJ; Kelton JG; Hirsh J; Cerskus A; Santos AV; Gent M
    Blood; 1982 Jun; 59(6):1239-45. PubMed ID: 7082826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits.
    Holmer E; Mattsson C; Nilsson S
    Thromb Res; 1982 Mar; 25(6):475-85. PubMed ID: 7112507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats.
    Andriuoli G; Mastacchi R; Barbanti M; Sarret M
    Haemostasis; 1985; 15(5):324-30. PubMed ID: 4076839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo effects of low molecular weight heparins on experimental thrombosis and bleeding.
    Hirsh J
    Haemostasis; 1986; 16(2):82-6. PubMed ID: 3710297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic effect of OP/LMWH by subcutaneous route in rats.
    Fantuz M; Milani R; Andriuoli G; Mastacchi R; Barbanti M
    Arch Int Pharmacodyn Ther; 1986 Aug; 282(2):328-34. PubMed ID: 3767531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the antithrombotic and haemorrhagic effects of a low molecular weight heparin (LHN-1) and conventional heparin.
    Diness V; Nielsen JI; Pedersen PC; Wolffbrandt KH; Ostergaard PB
    Thromb Haemost; 1986 Jun; 55(3):410-4. PubMed ID: 3750271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation.
    Cade JF; Buchanan MR; Boneu B; Ockelford P; Cater CJ; Cerskus AL; Hirsh J
    Thromb Res; 1984 Sep; 35(6):613-25. PubMed ID: 6506020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative.
    Kaiser B; Hauptmann J; Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):119-25. PubMed ID: 2459005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
    Berry CN; Girard D; Lochot S; Lecoffre C
    Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis.
    Iacoviello L; D'Adamo MC; Pawlak K; Polishchuck R; Wollny T; Buczko W; Donati MB
    Thromb Haemost; 1996 Dec; 76(6):1102-7. PubMed ID: 8972038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparins for the treatment of deep-vein thrombosis.
    Cziraky MJ; Spinler SA
    Clin Pharm; 1993 Dec; 12(12):892-9. PubMed ID: 8137606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative human pharmacology of low molecular weight heparins.
    Harenberg J; Stehle G; Augustin J; Zimmermann R
    Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction.
    Ockelford PA; Carter CJ; Mitchell L; Hirsh J
    Thromb Res; 1982 Nov; 28(3):401-9. PubMed ID: 7179224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
    Barrowcliffe TW; Thomas DP
    Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Low molecular weight heparins].
    Kher A; Bara L; Samama M
    Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.
    Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Watanabe M; Mochizuki H
    Thromb Haemost; 1997 Apr; 77(4):789-95. PubMed ID: 9134660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.